Filing Details
- Accession Number:
- 0001787306-24-000083
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-05-29 19:38:07
- Reporting Period:
- 2024-05-27
- Accepted Time:
- 2024-05-29 19:38:07
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1787306 | Arcutis Biotherapeutics Inc. | ARQT | Pharmaceutical Preparations (2834) | 812974255 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1798679 | Masaru Matsuda | C/O Arcutis Biotherapeutics, Inc. 3027 Townsgate Road, Suite 300 Westlake Village CA 91361 | See Remark | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-05-27 | 4,875 | $0.00 | 190,283 | No | 4 | A | Direct | |
Common Stock | Disposition | 2024-05-28 | 1,775 | $9.01 | 188,508 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | S | Direct |
Footnotes
- Represents performance stock units ("PSUs") initially granted on January 3, 2022 that were subject to a performance-based vesting condition. The vesting condition was determined to be satisfied on May 27, 2022. The PSUs will vest fully on May 27, 2025, subject to the Reporting Person's continued service to the Issuer on such vesting date.
- The sale was made pursuant to the Issuer's mandatory sell-to-cover requirements implemented to satisfy the tax withholding obligations associated with the vesting of the reporting person's PSUs.
- The transaction was executed in multiple trades in prices ranging from $8.99 to $9.02, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.